A deep bench against drug-resistant infection — one Phase 3-ready asset, one first-in-class lead in development, and earlier-stage candidates behind them.
Fedora is advancing a portfolio designed to address serious infections caused by drug-resistant bacteria, including a novel antibiotic and a β-lactamase inhibitor program.
A β-lactamase inhibitor with a unique dual mechanism — combining enzyme inhibition with direct antibacterial activity — for serious drug-resistant bacterial infections, including complicated urinary tract infections and carbapenem-resistant Enterobacterales.
A first-in-class, non-β-lactam penicillin-binding protein inhibitor derived from the lactivicin family of natural products — the first from this class to advance toward the clinic — with potent activity against multidrug-resistant Gram-negative pathogens.
Additional novel anti-infective programs leveraging Fedora's deep expertise in medicinal chemistry and antibacterial drug discovery to address critical unmet clinical needs.
Bacteria produce β-lactamase enzymes that destroy β-lactam antibiotics — penicillins, cephalosporins, and carbapenems. Those three classes account for over 60% of every antibiotic prescribed. Fedora's inhibitors shut the enzymes down and put the drugs back to work.
A Phase 3-ready β-lactamase inhibitor with broad-spectrum activity in combination with β-lactam antibiotics.
Fedora's programs are supported by strong science, experienced leadership, and compelling data. Let's move the next antibiotic toward patients together.
